CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26567358.
- Also identified by DOI 10.1158/1078-0432.CCR-14-3129.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Circulating tumor cells (CTC) have substantial promise for multipurpose biomarker studies in prostate cancer. The IMMC-38 trial conducted by de Bono and colleagues, which was published in the October 1, 2008, issue of Clinical Cancer Research, demonstrated for the first time that CTCs are the most accurate and independent predictor of overall survival in metastatic prostate cancer. Since the publication of prospective trials demonstrating prognostic utility, CTCs have been utilized for nucleic acid analyses, for protein analyses, and in intermediate endpoint studies. CTC studies are also now facilitating the analysis of intrapatient heterogeneity. See related article by de Bono et al., Clin Cancer Res 2008;14(19) October 1, 2008;6302-9.
Medical subject headings
- Drug Resistance, Neoplasm
- Neoplastic Cells, Circulating
- Prostatic Neoplasms